Given that sustained AR signaling attributed to the truncated AR variants or AR overexpression is the major mechanism underlying the therapy resistance in advanced prostate cancer, we anticipate that simultaneously degrading both AR-FL and constitutively active AR-Vs is an efficient alternative approach to intervene CRPC and overcome anti-androgen drug resistance. The gene discussed is AR; the disease is prostate carcinoma.